Avalo Therapeutics (NASDAQ:AVTX) Earns Outperform Rating from Wedbush

Avalo Therapeutics (NASDAQ:AVTX)‘s stock had its “outperform” rating restated by stock analysts at Wedbush in a report released on Thursday,RTT News reports. They currently have a $18.00 price target on the stock. Wedbush’s price objective would indicate a potential upside of 134.99% from the company’s previous close. Wedbush also issued estimates for Avalo Therapeutics’ Q1 2025 earnings at $0.63 EPS.

AVTX has been the topic of a number of other reports. Piper Sandler assumed coverage on Avalo Therapeutics in a research note on Friday, February 28th. They issued an “overweight” rating and a $48.00 target price on the stock. BTIG Research assumed coverage on Avalo Therapeutics in a research note on Thursday, December 19th. They issued a “buy” rating and a $40.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Avalo Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $35.33.

Avalo Therapeutics Stock Performance

Shares of NASDAQ AVTX opened at $7.66 on Thursday. The stock’s 50-day simple moving average is $7.45 and its two-hundred day simple moving average is $9.11. Avalo Therapeutics has a twelve month low of $4.60 and a twelve month high of $34.46.

Hedge Funds Weigh In On Avalo Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. RA Capital Management L.P. bought a new position in Avalo Therapeutics during the 3rd quarter worth approximately $9,186,000. Ikarian Capital LLC grew its position in Avalo Therapeutics by 1,673.0% during the 3rd quarter. Ikarian Capital LLC now owns 970,359 shares of the company’s stock worth $9,218,000 after acquiring an additional 915,629 shares during the last quarter. Northern Trust Corp bought a new position in Avalo Therapeutics during the 4th quarter worth approximately $168,000. Velan Capital Investment Management LP bought a new position in Avalo Therapeutics during the 4th quarter worth approximately $817,000. Finally, Tower Research Capital LLC TRC grew its position in Avalo Therapeutics by 998.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock worth $31,000 after acquiring an additional 3,754 shares during the last quarter. 87.06% of the stock is currently owned by institutional investors.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.